查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1993054

肺氣腫治療市場：2026-2032年全球市場預測（依治療方法、藥物類別、治療線、給藥途徑、劑型、產品類型及分銷管道分類）

Emphysema Treatment Market by Treatment Type, Drug Class, Therapy Line, Route Of Administration, Dosage Form, Product Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，肺氣腫治療市場價值將達到 73.2 億美元，到 2026 年將成長至 78.4 億美元，到 2032 年將達到 119.4 億美元，複合年成長率為 7.23%。

主要市場統計數據
基準年 2025 73.2億美元
預計年份：2026年 78.4億美元
預測年份 2032 119.4億美元
複合年成長率 (%) 7.23%

全面介紹不斷變化的肺氣腫治療格局、臨床重點以及影響治療決策的新挑戰。

由於肺氣腫具有進行性發展、症狀負擔重和醫療資源消耗高等特點，因此在慢性呼吸系統疾病的治療中，它仍然是臨床和商業性領域的重點領域。肺氣腫的整體情況包括藥物治療和手術治療，兩者各有不同的臨床目標。藥物治療旨在抑制發炎、緩解氣流阻塞和減少急性加重，而手術治療則僅限於經過嚴格篩選、旨在改善肺功能和生活品質的患者。本導言概述了許多正在重塑患者照護、創新研發管線和支付方格局的因素。

藥物治療、器械管理和手術方面的創新如何重塑肺氣腫治療路徑和相關人員的期望。

肺氣腫治療的現狀正經歷著一場變革，其驅動力來自藥物治療的創新、外科技術的改進以及對綜合護理模式日益成長的重視。新型聯合治療和器械平台正在拓展臨床選擇，而微創手術和瓣膜治療則為過去選擇有限的患者提供了新的希望。這些變化並非孤立發生，而是與監管決策、報銷途徑和臨床指南的更新相互作用，從而加速了特定干涉措施的推廣應用。

2025 年美國關稅重組對肺氣腫治療供應鏈、採購韌性和臨床連續性的營運和策略影響。

2025年美國關稅和貿易政策變化所帶來的累積影響，為醫療器材製造商和經銷商創造了一個必須謹慎應對的商業環境。關稅表的變化影響了專用吸入器、某些生物製藥成分以及用於高級肺部手術的外科器械的進口成本。為此，製造商加快了對其供應鏈的重新評估、採購合約的重新談判以及關鍵零件的在地採購，以降低貿易相關的成本波動風險。

多方面的細分洞察揭示了治療類型、藥物類別、治療線和供應途徑如何決定臨床應用和商業性定位。

關鍵的市場區隔洞察揭示了不同治療方法類型、藥物分類、治療線、給藥途徑、劑型、分銷管道和產品類型在治療方法選擇和商業性策略上的差異。根據治療類型，市場可區分正在研究的藥物治療方案（例如抗生素、支氣管擴張劑、皮質類固醇和祛痰藥）和外科手術方案（包括膀胱切除術、肺移植、肺減容術和瓣膜治療）。這種二分法凸顯了整合藥物最佳化和治療選擇標準的協調護理路徑的必要性。

美洲、歐洲、中東和非洲以及亞太地區在監管、報銷和醫療保健服務方面的區域差異如何影響醫療服務取得和商業化策略？

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的臨床實踐、法律規範和商業策略都產生了重大影響。在美洲，對整合式醫療保健系統和基於價值的醫療模式的重視，使得能夠顯著減少住院次數並改善患者長期預後的治療方法和干涉措施成為優先事項，這促使支付方和醫療服務提供者仔細審查療效比較和總醫療成本。這種環境推動了人們對長期維持療法和支持用藥依從性的醫療設備創新日益成長的興趣。

為滿足肺氣腫治療的多方面需求，推動藥物治療、醫療設備和手術解決方案發展的公司的競爭概況和策略挑戰。

肺氣腫治療領域的競爭格局由眾多參與者所構成，包括成熟的製藥公司、專業的醫療設備製造商以及致力於研發創新治療方法的生技公司。成熟公司憑藉其豐富的呼吸系統產品系列、與醫療專業人士的緊密聯繫以及完善的分銷網路，在醫院和零售通路中保持著穩固的市場地位。同時，新參與企業則專注於差異化的作用機制、標靶的醫療設備與藥物組合或手術創新，力求開闢臨床與商業性上的利基市場。策略聯盟和許可協議仍然至關重要，因為各公司都希望將臨床專業知識與醫療設備工程相結合，並透過合作開發加速市場進入。

為產業領導者提供切實可行的策略建議，以協調臨床證據、醫療設備創新、供應鏈韌性和進入本地市場。

產業領導者應制定一套切實可行的建議，以協調臨床差異化、商業性可行性和營運韌性。首先，應優先創建整合證據，將隨機對照試驗數據與真實世界臨床結果相結合，重點關注諸如減少病情加重、避免住院和提高生活品質等指標，以滿足支付方和指南的要求。將這些臨床數據轉化為清晰的價值提案，既要考慮短期資源影響，又要兼顧長期健康效益。

採用以證據主導的調查方法，結合系統性文獻回顧、對臨床醫生和管理人員的訪談以及供應鏈政策分析來檢驗研究結果。

本分析的調查方法結合了嚴謹的二手資料分析和有針對性的定性研究，以確保其具有全面且基於證據的觀點。對同行評審的臨床文獻、監管指南和公共衛生指南的系統性回顧提供了其臨床和科學背景。除此之外，本研究也透過評估醫療設備核准情況、手術相關文獻和技術評估報告，捕捉了藥物治療和外科領域的進展。

一項權威的綜合分析強調了臨床創新、營運韌性和區域特定市場策略對於肺氣腫治療成功的關鍵作用。

總之，肺氣腫治療目前正處於一個轉折點，藥物療效的提升、給藥方式的創新以及手術技術的進步，與不斷變化的支付方期望和區域差異交織在一起。臨床決策越來越以對患者和醫療保健系統至關重要的結果為導向，相關人員也透過強調持續維持治療、利用更先進的醫療設備提高遵守用藥以及精準選擇手術適應症來應對這一趨勢。這些趨勢為兼顧臨床療效、擴充性和經濟合理性的差異化治療策略創造了機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療方法分類的肺氣腫治療市場

  • 藥物治療
    • 抗生素
    • 支氣管擴張劑
    • 皮質類固醇
    • 祛痰藥
  • 外科
    • 切除術
    • 肺移植
    • 肺減容手術
    • 瓣膜治療

第9章：肺氣腫治療市場：依藥物類別分類

  • 抗膽鹼能藥物
  • BETA-激動劑
  • 組合藥物

第10章：依治療方法分類的肺氣腫治療市場

  • 輔助性治療
  • 第一選擇
  • 維持治療
    • 聯合治療
    • 長效抗膽鹼能藥物
    • 長效BETA-激動劑
  • 急診醫學
    • 短效抗膽鹼能藥物
    • 短效BETA-激動劑

第11章：肺氣腫治療市場：依給藥途徑分類

  • 吸入
    • 乾粉吸入器
    • 定量吸入器
    • 噴霧器
    • 緩霧吸入器
  • 靜脈
    • 靜脈注射
    • 注射
  • 口服
    • 膠囊
    • 解決方案
    • 藥片

第12章：以劑型分類的肺氣腫治療市場

  • 膠囊
  • 吸入器
  • 噴霧器
  • 解決方案
  • 藥片

第13章：肺氣腫治療市場：依產品類型分類

  • 品牌商品
  • 非專利的

第14章：肺氣腫治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第15章：肺氣腫治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：肺氣腫治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 肺氣腫治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國肺氣腫治療市場

第19章 中國肺氣腫治療市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Chiesi Farmaceutici SpA
  • Cipla Limited
  • GlaxoSmithKline plc
  • Grifols SA
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Olympus Corporation
  • Orion Corporation
  • Pfizer, Inc.
  • Pulmonx Corporation
  • ResMed, Inc.
  • Roche Holding AG
  • Sandoz International GmbH
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd
  • Theravance Biopharma, Inc.
  • Verona Pharma plc
  • Viatris Inc.
Product Code: MRR-1A1A064C021A

The Emphysema Treatment Market was valued at USD 7.32 billion in 2025 and is projected to grow to USD 7.84 billion in 2026, with a CAGR of 7.23%, reaching USD 11.94 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.32 billion
Estimated Year [2026] USD 7.84 billion
Forecast Year [2032] USD 11.94 billion
CAGR (%) 7.23%

A comprehensive introduction outlining the evolving emphysema treatment environment, clinical priorities, and emerging pressures shaping therapeutic decision-making

Emphysema remains a clinical and commercial priority within chronic respiratory disease management, driven by its progressive pathology, symptomatic burden, and high healthcare utilization. The therapeutic landscape comprises both pharmacological and surgical approaches, each carrying distinct clinical objectives: pharmacological strategies aim to control inflammation, relieve airflow obstruction, and reduce exacerbations, while surgical options are reserved for carefully selected patients to improve lung mechanics and quality of life. This introduction frames the converging forces reshaping patient care, innovation pipelines, and the payer environment.

Over recent years, clinical practice has shifted toward personalized treatment pathways that integrate long-acting bronchodilators, targeted anti-inflammatory regimens, and precision selection for surgical intervention. Advances in device technology and procedural techniques have refined therapeutic delivery, improving tolerability and adherence. At the same time, health systems are emphasizing value-based outcomes, prompting stakeholders to reevaluate treatment appropriateness, long-term management strategies, and interventions that meaningfully reduce hospital admissions.

Given these dynamics, industry participants-spanning drug developers, device manufacturers, payers, and provider networks-must reconcile clinical evidence with operational realities to design scalable solutions. This introduction sets the stage for a deeper exploration of how shifting scientific, regulatory, and economic pressures create both constraints and opportunities across the continuum of emphysema care.

How innovations in pharmacotherapy, device delivery, and procedural techniques are reshaping emphysema care pathways and stakeholder expectations

The landscape of emphysema treatment is undergoing transformative shifts driven by innovation in pharmacotherapy, refinement of surgical techniques, and a growing emphasis on integrated care models. Novel drug combinations and device platforms are expanding clinical options, while minimally invasive procedures and valve therapies provide alternatives for patients who historically had limited choices. These changes are not isolated; they interact with regulatory decisions, reimbursement pathways, and clinical guideline updates to accelerate adoption curves for certain interventions.

Concurrently, the shift toward patient-centered care has elevated metrics such as quality of life, exercise tolerance, and exacerbation reduction over simple physiological markers. This reorientation compels developers to demonstrate real-world effectiveness and durability of benefit. Advances in inhalation technologies, including dry powder and soft mist inhalers, are increasing the precision and convenience of drug delivery, thereby improving adherence and therapeutic effect. On the surgical side, refinements in lung volume reduction surgery and bronchoscopic valve therapy are generating new evidence for subgroup benefit, prompting multidisciplinary teams to reevaluate candidacy criteria.

These transformative shifts are amplified by digital health integration, remote monitoring, and telemedicine-enabled follow-up, which collectively support early intervention and tailored maintenance strategies. As stakeholders respond, the market is recalibrating toward interventions that can provide measurable patient benefit while aligning with payer expectations for cost-effectiveness and demonstrable outcomes.

Operational and strategic consequences of United States tariff realignments in 2025 on supply chains, procurement resilience, and clinical continuity for emphysema therapies

The cumulative impact of tariff and trade policy changes in the United States in 2025 created an operational context that healthcare manufacturers and distributors had to navigate carefully. Shifts in tariff schedules affected the importation costs of specialized inhalation devices, certain biopharmaceutical components, and surgical equipment used in advanced pulmonary procedures. Manufacturers responded by reassessing supply chains, renegotiating sourcing agreements, and accelerating localization of critical components to mitigate exposure to trade-related cost volatility.

These adjustments reverberated downstream, influencing procurement strategies for hospital systems and integrated care networks that procure a mix of pharmacological therapies and procedural devices. Some organizations shifted toward longer term contracting and regional supplier diversification to minimize disruptions. Regulatory and customs compliance requirements also increased administrative overhead, prompting stakeholders to invest in supply chain resilience and scenario planning.

Importantly, the policy environment catalyzed conversations about domestic manufacturing capacity and strategic inventory management for high-value components. The aggregate effect was a renewed focus on manufacturing agility and risk mitigation across the product lifecycle, with commercial teams integrating tariff sensitivity into pricing, contracting, and go-to-market planning to preserve access and maintain clinical continuity for patients reliant on complex emphysema treatments.

Multidimensional segmentation insights revealing how treatment type, drug class, therapy line, and delivery channels dictate clinical adoption and commercial positioning

Key segmentation insights illuminate how therapeutic choices and commercial pathways diverge across treatment type, drug class, therapy line, route of administration, dosage form, distribution channel, and product type. Based on treatment type, the market distinguishes pharmacological options-studied across antibiotics, bronchodilators, corticosteroids, and mucolytics-from surgical approaches that include bullectomy, lung transplantation, lung volume reduction surgery, and valve therapy; this dichotomy underscores the need for coordinated care pathways that integrate medication optimization with procedural selection criteria.

When considered through the lens of drug class, anticholinergics, beta-agonists, and combination drugs dominate clinical strategies for bronchodilation and symptom control, and their evolving formulations and delivery systems directly influence adherence and clinical outcomes. Therapy line segmentation-adjunctive, first-line, maintenance, and rescue-reveals how interventions are positioned across the patient journey; within maintenance strategies, combination therapy, long-acting anticholinergics, and long-acting beta-agonists are central to sustained disease control, while rescue options rely on short-acting anticholinergics and short-acting beta-agonists to address acute symptom flares.

Route of administration is a critical commercial and clinical differentiator: inhalation modalities such as dry powder inhaler, metered dose inhaler, nebulizer, and soft mist inhaler remain primary for chronic management, whereas intravenous approaches-infusion and injection-are typically reserved for acute care or hospital-based interventions, and oral formulations including capsule, solution, and tablet provide convenience for certain therapeutic classes. Dosage form segmentation across capsule, inhaler, nebulizer, solution, and tablet aligns closely with route considerations and patient adherence profiles. Distribution channel patterns-hospital pharmacy, online pharmacy, and retail pharmacy-reflect evolving purchasing behaviors and the increasing relevance of omnichannel access to therapies. Finally, product type segmentation between brand and generic options determines pricing dynamics, formulary placement, and uptake, particularly where generics enable broader access but branded innovations support premium positioning. Collectively, these segmentation lenses offer a multidimensional view that informs product development, commercial targeting, and clinical pathway design.

How regional regulatory, reimbursement, and healthcare delivery differences across the Americas, Europe Middle East & Africa, and Asia-Pacific shape access and commercialization strategies

Regional dynamics exert a strong influence on clinical practice, regulatory frameworks, and commercial strategy across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, emphasis on integrated health systems and value-based care models has prioritized therapies and interventions that demonstrably reduce hospitalizations and improve long-term patient outcomes, prompting payers and providers to scrutinize comparative effectiveness and total cost of care. This environment fuels interest in durable maintenance regimens and device innovations that support adherence.

Within Europe, Middle East & Africa, diverse regulatory pathways and heterogeneous healthcare funding mechanisms require tailored market access plans that account for country-specific reimbursement criteria and clinical guideline adoption. Stakeholders in this region often balance innovative therapeutics with local affordability considerations, creating opportunities for differentiated access strategies that pair clinical evidence with pragmatic pricing models. Across Asia-Pacific, rapid adoption of advanced inhalation technologies and growing investment in specialist pulmonary services are expanding the addressable patient population for both pharmacological and procedural interventions; however, variations in healthcare infrastructure and reimbursement across countries necessitate flexible commercialization approaches.

These regional distinctions underscore the importance of aligning clinical development and market access activities with localized evidence generation, stakeholder engagement, and distribution strategies. Companies that tailor their evidence packages, delivery modalities, and pricing structures to regional priorities are better positioned to achieve sustainable adoption and to scale interventions across multiple healthcare contexts.

Competitive profile and strategic imperatives for companies advancing pharmacological, device-based, and procedural solutions to address multifaceted emphysema care needs

Competitive dynamics in emphysema treatment are shaped by a mix of established pharmaceutical companies, specialized device manufacturers, and emerging biotech organizations pursuing novel therapeutic modalities. Incumbent players leverage broad respiratory portfolios, deep clinician relationships, and distribution networks to maintain access across hospitals and retail channels, while emerging entrants focus on differentiated mechanisms, targeted device-drug combinations, or procedural innovation to create clinical and commercial niches. Strategic partnerships and licensing agreements remain pivotal as companies aim to combine clinical expertise with device engineering or to accelerate market entry through co-development.

R&D intensity is concentrated on improving patient outcomes through longer-acting agents, combination formulations, and inhaler technologies that reduce systemic exposure and improve adherence. On the procedural side, device refinements and improved patient selection algorithms are expanding the candidate pool for lung volume reduction and valve therapies. Corporate strategy increasingly blends lifecycle management of legacy products with targeted investment in evidence generation to support label expansion or new guideline recommendations.

M&A and alliance activity gravitates toward capability gaps-such as inhalation device platforms or digital health solutions that enable remote monitoring and adherence support. Companies that can demonstrate integrated value propositions combining clinical efficacy, improved patient experience, and logistical simplicity stand to gain traction with payers and providers. Overall, competitive success hinges on evidence-driven differentiation, agile commercialization models, and close engagement with multidisciplinary clinical teams.

Actionable strategic recommendations for industry leaders to align clinical evidence, device innovation, supply chain resilience, and regional market access execution

Industry leaders should pursue a set of actionable recommendations that align clinical differentiation with commercial pragmatism and operational resilience. First, prioritize integrated evidence generation that pairs randomized controlled trial data with real-world outcomes, emphasizing measures such as exacerbation reduction, hospitalization avoidance, and quality of life improvements to meet payer and guideline expectations. Translate these clinical data into clear value narratives that address both short-term resource impact and long-term health benefits.

Second, invest in device and formulation optimization to enhance adherence and patient experience; innovations that simplify dosing, reduce handling complexity, or improve delivery efficiency can materially affect therapeutic efficacy in routine practice. Third, strengthen supply chain resilience by diversifying suppliers, localizing critical manufacturing capabilities where feasible, and incorporating tariff sensitivity into procurement and pricing models to reduce exposure to trade disruption. Fourth, tailor market access strategies to regional realities by developing country-specific evidence packages and adaptive pricing approaches that respect local reimbursement frameworks while preserving commercial viability.

Fifth, pursue strategic partnerships that combine clinical expertise, device engineering, and digital health capabilities to create bundled solutions that resonate with multidisciplinary care teams. Finally, embed patient-centricity across development and commercial activities by leveraging patient-reported outcomes, adherence analytics, and support programs that facilitate sustained engagement. These recommendations together support robust clinical uptake and sustainable commercial performance.

An evidence-driven research methodology blending systematic literature review, clinician and executive interviews, and supply chain policy analysis to validate insights

The research methodology underpinning this analysis combined rigorous secondary intelligence with targeted qualitative engagement to ensure a comprehensive, evidence-based perspective. A systematic review of peer-reviewed clinical literature, regulatory guidance, and public health directives provided the foundational clinical and scientific context. This review was complemented by an appraisal of device approvals, procedural technique literature, and technology assessment reports to capture advancements in both pharmacological and surgical domains.

To enrich the secondary evidence base, structured interviews were conducted with clinical specialists, procurement leaders, and industry executives to surface practical insights on treatment adoption, patient selection, and operational constraints. These qualitative engagements helped validate trends observed in the literature and clarified how reimbursement and delivery models influence real-world decision-making. The methodology also included an assessment of supply chain and policy developments, focusing on how tariff adjustments and trade policy changes affect manufacturing and distribution strategies.

Data synthesis emphasized triangulation across sources to reduce bias and to highlight convergent conclusions. Limitations were acknowledged where evidence gaps persist, and recommendations were framed to be actionable within the context of identified uncertainties. This methodological approach ensures that the conclusions are grounded in multifaceted evidence and validated practitioner perspectives.

A conclusive synthesis emphasizing how clinical innovation, operational resilience, and localized market strategies will determine success in emphysema treatment

In conclusion, the emphysema treatment landscape is at an inflection point where pharmacological refinements, delivery innovations, and procedural advances converge with evolving payer expectations and regional heterogeneity. Clinical decision-making is increasingly guided by outcomes that matter to patients and health systems, and stakeholders are responding by emphasizing durable maintenance regimens, improved adherence through better devices, and precise surgical selection. These dynamics create opportunities for differentiated therapeutic strategies that combine clinical effectiveness with scalability and economic rationale.

Operationally, trade policy shifts and supply chain pressures underscore the need for manufacturers and distributors to enhance resilience and to incorporate policy sensitivity into commercial planning. Region-specific approaches will be essential, as regulatory frameworks, reimbursement models, and healthcare delivery capacities vary substantially across markets. Competitive success will favor organizations that integrate robust evidence generation, strategic partnerships, and patient-centric product design.

Moving forward, decision-makers should adopt a balanced strategy that prioritizes clinical value, operational agility, and localized market access plans. By aligning innovation with pragmatic execution, stakeholders can improve patient outcomes while navigating the complex commercial and policy landscape that frames contemporary emphysema care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Emphysema Treatment Market, by Treatment Type

  • 8.1. Pharmacological
    • 8.1.1. Antibiotics
    • 8.1.2. Bronchodilators
    • 8.1.3. Corticosteroids
    • 8.1.4. Mucolytics
  • 8.2. Surgical
    • 8.2.1. Bullectomy
    • 8.2.2. Lung Transplantation
    • 8.2.3. Lung Volume Reduction Surgery
    • 8.2.4. Valve Therapy

9. Emphysema Treatment Market, by Drug Class

  • 9.1. Anticholinergics
  • 9.2. Beta-Agonists
  • 9.3. Combination Drugs

10. Emphysema Treatment Market, by Therapy Line

  • 10.1. Adjunctive
  • 10.2. First-Line
  • 10.3. Maintenance
    • 10.3.1. Combination Therapy
    • 10.3.2. Long-Acting Anticholinergics
    • 10.3.3. Long-Acting Beta-Agonists
  • 10.4. Rescue
    • 10.4.1. Short-Acting Anticholinergics
    • 10.4.2. Short-Acting Beta-Agonists

11. Emphysema Treatment Market, by Route Of Administration

  • 11.1. Inhalation
    • 11.1.1. Dry Powder Inhaler
    • 11.1.2. Metered Dose Inhaler
    • 11.1.3. Nebulizer
    • 11.1.4. Soft Mist Inhaler
  • 11.2. Intravenous
    • 11.2.1. Infusion
    • 11.2.2. Injection
  • 11.3. Oral
    • 11.3.1. Capsule
    • 11.3.2. Solution
    • 11.3.3. Tablet

12. Emphysema Treatment Market, by Dosage Form

  • 12.1. Capsule
  • 12.2. Inhaler
  • 12.3. Nebulizer
  • 12.4. Solution
  • 12.5. Tablet

13. Emphysema Treatment Market, by Product Type

  • 13.1. Brand
  • 13.2. Generic

14. Emphysema Treatment Market, by Distribution Channel

  • 14.1. Hospital Pharmacy
  • 14.2. Online Pharmacy
  • 14.3. Retail Pharmacy

15. Emphysema Treatment Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Emphysema Treatment Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Emphysema Treatment Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Emphysema Treatment Market

19. China Emphysema Treatment Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Amgen Inc.
  • 20.6. Astellas Pharma Inc.
  • 20.7. AstraZeneca plc
  • 20.8. Baxter International Inc.
  • 20.9. Boehringer Ingelheim International GmbH
  • 20.10. Boston Scientific Corporation
  • 20.11. Chiesi Farmaceutici S.p.A.
  • 20.12. Cipla Limited
  • 20.13. GlaxoSmithKline plc
  • 20.14. Grifols S.A.
  • 20.15. Johnson & Johnson Services, Inc.
  • 20.16. Merck & Co., Inc.
  • 20.17. Mylan N.V.
  • 20.18. Novartis AG
  • 20.19. Olympus Corporation
  • 20.20. Orion Corporation
  • 20.21. Pfizer, Inc.
  • 20.22. Pulmonx Corporation
  • 20.23. ResMed, Inc.
  • 20.24. Roche Holding AG
  • 20.25. Sandoz International GmbH
  • 20.26. Sanofi S.A.
  • 20.27. Sunovion Pharmaceuticals Inc.
  • 20.28. Teva Pharmaceutical Industries Ltd
  • 20.29. Theravance Biopharma, Inc.
  • 20.30. Verona Pharma plc
  • 20.31. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EMPHYSEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL EMPHYSEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA EMPHYSEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MUCOLYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MUCOLYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BULLECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BULLECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BULLECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG VOLUME REDUCTION SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG VOLUME REDUCTION SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG VOLUME REDUCTION SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY VALVE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY VALVE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY VALVE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BETA-AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BETA-AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BETA-AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ADJUNCTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ADJUNCTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ADJUNCTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY FIRST-LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING BETA-AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING BETA-AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING BETA-AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING BETA-AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING BETA-AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING BETA-AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRY POWDER INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRY POWDER INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY METERED DOSE INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY METERED DOSE INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOFT MIST INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOFT MIST INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOFT MIST INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRAND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRAND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRAND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 288. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 289. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 290. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 291. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 292. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 293. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 294. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 295. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 296. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 297. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 298. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 330. G7 EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 331. G7 EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. G7 EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 333. G7 EMPHYSEMA TREATMENT MARKET SIZE, BY SURGI